SanBio has been granted a patent for a method and culture medium to induce polarization in multipotent stem cells, producing therapeutic cells and extracellular vesicles. The method involves using specific agents and ligands to induce expression of CXCL9 in the cells. GlobalData’s report on SanBio gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on SanBio, NSAID cancer drugs was a key innovation area identified from patents. SanBio's grant share as of April 2024 was 56%. Grant share is based on the ratio of number of grants to total number of patents.
Method for inducing polarization in stem cells for therapy
A recently granted patent (Publication Number: US11946072B2) discloses a method for producing an immunologically polarized mesenchymal stem cell population from an unstimulated mesenchymal stem cell population. The method involves contacting the unstimulated cells with a culture medium containing a Toll-like receptor 3 (TLR3) ligand and an agent such as acetylcholine, norepinephrine, epinephrine, serotonin, or melatonin, leading to the induction of CXCL9 expression in the resulting immunologically polarized mesenchymal stem cell population. Additionally, the TLR3 ligand can include poly (I:C), poly (A:U), or a combination of both, with the culture medium potentially further comprising erythropoietin.
Furthermore, the method includes conducting the culture under hypoxic conditions, with varying oxygen levels ranging from less than 8% to as low as 0.5-3.0%. The concentration of the agent, particularly acetylcholine, in the culture medium can range from 1 nanomolar (nM) to 100 micromolar (µM), with different concentrations specified for optimal results. The duration of contact between the unstimulated mesenchymal stem cell population and the culture medium is also defined, with the process lasting less than 24 hours or exceeding 1 hour. These specific conditions and parameters outlined in the patent aim to efficiently generate an immunologically polarized mesenchymal stem cell population with induced CXCL9 expression, potentially offering new avenues for therapeutic applications in the field of regenerative medicine.
To know more about GlobalData’s detailed insights on SanBio, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
